+ Resolve Article
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter

+ Translate
+ Subscribe to Site Feed
GeoScience Most Shared ContentMost Shared Content

Chimeric antigen receptor T cells for sustained remissions in leukemia

, : Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine 371(16): 1507-1517

Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies. Chimeric antigen receptor-modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission in patients with refractory disease. We infused autologous T cells transduced with a CD19-directed chimeric antigen receptor (CTL019) lentiviral vector in patients with relapsed or refractory ALL at doses of 0.76×10(6) to 20.6×10(6) CTL019 cells per kilogram of body weight. Patients were monitored for a response, toxic effects, and the expansion and persistence of circulating CTL019 T cells. A total of 30 children and adults received CTL019. Complete remission was achieved in 27 patients (90%), including 2 patients with blinatumomab-refractory disease and 15 who had undergone stem-cell transplantation. CTL019 cells proliferated in vivo and were detectable in the blood, bone marrow, and cerebrospinal fluid of patients who had a response. Sustained remission was achieved with a 6-month event-free survival rate of 67% (95% confidence interval [CI], 51 to 88) and an overall survival rate of 78% (95% CI, 65 to 95). At 6 months, the probability that a patient would have persistence of CTL019 was 68% (95% CI, 50 to 92) and the probability that a patient would have relapse-free B-cell aplasia was 73% (95% CI, 57 to 94). All the patients had the cytokine-release syndrome. Severe cytokine-release syndrome, which developed in 27% of the patients, was associated with a higher disease burden before infusion and was effectively treated with the anti-interleukin-6 receptor antibody tocilizumab. Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL. CTL019 was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed. (Funded by Novartis and others; CART19 numbers, NCT01626495 and NCT01029366.).


PMID: 25317870

DOI: 10.1056/NEJMoa1407222

Other references

Wlochowicz, A., 1985: Topography of changes in selected wool fibre parameters on sheep body. Differences in the molecular and supermolecular structures (crystallinity, crystalline orientation, cystine content and degree of damage) of fibres taken from 16 areas on the body were examined in wool samples from Polish Merino crossbreds and Rom...

Mion, F.B.; Faure, J.L.; Berger, F.; McGregor, B.; Perrot, H.; Paliard, P., 1992: Liver transplantation for erythropoietic protoporphyria. Report of a new case with subsequent medium-term follow-up. We report a new case of successful liver transplantation in a 36-year-old patient with terminal hepatic failure due to erythropoietic protoporphyria. Data regarding protoporphyrin levels in erythrocytes and feces, before and after transplantation,...

Wu, N.; Hao, F.; Yu, X., 2012: Peripheral nerve and skin damage associated with working in a STCP factory: report of four cases. Sodium 3,5,6-trichloropyridin-2-ol (STCP) is a widely used intermediate for the production of chlorpyrifos. However, its effect on the health of workers in STCP factories has become increasingly problematic. This article reports four workers who w...

Anonymous, 1983: 'Misjudgement' over Veterinary Surgeons Act. The Veterinary Record 112: 6-90

Munshaw, S.; Bailey, J.R.; Liu, L.; Osburn, W.O.; Burke, K.P.; Cox, A.L.; Ray, S.C., 2012: Computational reconstruction of Bole1a, a representative synthetic hepatitis C virus subtype 1a genome. Hepatitis C virus (HCV) research is hampered by the use of arbitrary representative isolates in cell culture and immunology. The most replicative isolate in vitro is a subtype 2a virus (JFH-1); however, genotype 1 is more prevalent worldwide and r...

L'Abbate, A.; Marzilli, M.; Ballestra, A.M.; Taddei, L.; Camici, P.; Mariani, F.; Maseri, A., 1976: Effect of contraction on the distribution of coronary flow. Bollettino Della Societa Italiana di Cardiologia 21(9): 1503-1508

Anonymous, 1991: It's All In The Genes. Inpharma Weekly 814(1): 2-3

Wang, X.; Wang, L.; Sheng, X.; Huang, Z.; Li, T.; Zhang, M.; Xu, J.; Ji, H.; Yin, J.; Zhang, Y., 2015: Design, synthesis and biological evaluation of hydrogen sulfide releasing derivatives of 3-n-butylphthalide as potential antiplatelet and antithrombotic agents. In the present study, a series of hydrogen sulfide (H2S) releasing derivatives (8a–g and 9a–f) of 3-n-butylphthalide (NBP) were designed, synthesized and biologically evaluated. The most promising compound 8e significantly inhibited the adenos...

Franz G.; Harms U.; Denkler T.; Pasteels P., 1993: Late Cretaceous igneous activity in the Delgo uplift (Northern Province, Sudan). Pages 227-230 1993

Von Zup, M.; Lassaline, M.; Kass, P.H.; Miller, P.E.; Thomasy, S.M., 2017: Effects of 0.2% brimonidine and 0.2% brimonidine-0.5% timolol on intraocular pressure and pupil size in normal equine eyes. Brimonidine is an α<sub>2</sub> -adrenergic agonist that decreases aqueous humour production and may increase uveoscleral outflow. It has not been evaluated in normal or glaucomatous equine eyes. To evaluate the efficacy and safety of...